MoonLake Immunotherapeutics(MLTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MLTX MoonLake Immunotherapeutics

Pre-Mkt 12-23 06:51:30 EST

13.49

+0.10

+0.75%

High13.81	Low13.32	Vol1.45M
Open13.45	D1 Closing13.39	Amplitude3.66%
Mkt Cap962.83M	Tradable Cap545.21M	Total Shares71.37M
T/O19.65M	T/O Rate3.59%	Tradable Shares40.42M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MLTX","market":"US","secType":"STK","nameCN":"MoonLake Immunotherapeutics","latestPrice":13.49,"timestamp":1766437200000,"preClose":13.39,"halted":0,"volume":1450713,"delay":0,"floatShares":40415700,"shares":71373579,"eps":-3.328528,"marketStatus":"Pre-Mkt","change":0.1,"latestTime":"12-23 06:51:30 EST","open":13.45,"high":13.81,"low":13.3205,"amount":19649002.340088,"amplitude":0.036557,"askPrice":14.61,"askSize":100,"bidPrice":13.2,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-3.328528,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1766500200000},"marketStatusCode":1,"adr":0,"listingDate":1603166400000,"exchange":"NASDAQ","adjPreClose":13.49,"postHourTrading":{"tag":"盘后","latestPrice":13.4684,"preClose":13.49,"latestTime":"19:17 EST","volume":56961,"amount":768334.048,"timestamp":1766449057467},"volumeRatio":0.9299042513379334,"impliedVol":1.3174,"impliedVolPercentile":0.8554},"requestUrl":"/m/hq/s/MLTX/tweets","defaultTab":"tweets","newsList":[{"id":"2591164640","title":"MoonLake Immunotherapeutics Faces Securities Fraud Class Action","url":"https://stock-news.laohu8.com/highlight/detail?id=2591164640","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591164640?lang=en_us&edition=fundamental","pubTime":"2025-12-15 20:42","pubTimestamp":1765802537,"startTime":"0","endTime":"0","summary":"A class action lawsuit has been filed against Moonlake Immunotherapeutics on behalf of investors who suffered losses between March 10, 2024 and September 29, 2025. The complaint alleges that the company made false statements and concealed key information regarding its sole drug candidate, SLK. Specifically, it is claimed that SLK and BIMZELX share the same molecular targets, and that SLK's unique Nanobody structure would not deliver superior clinical benefits or efficacy compared to the traditional monoclonal structure of BIMZELX. The lawsuit contends that Moonlake Immunotherapeutics lacked a reasonable basis for its positive statements about SLK's superiority over monoclonal antibodies. The legal action seeks to recover damages for affected investors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and shou","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL2bc3ly:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLTX","BK4139"],"gpt_icon":0},{"id":"2590179506","title":"MoonLake Immunotherapeutics Faces Class Action Lawsuit Over Securities Fraud Allegations","url":"https://stock-news.laohu8.com/highlight/detail?id=2590179506","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590179506?lang=en_us&edition=fundamental","pubTime":"2025-12-12 20:42","pubTimestamp":1765543341,"startTime":"0","endTime":"0","summary":"A class action lawsuit has been filed against Moonlake Immunotherapeutics, alleging securities fraud that affected investors between March 10, 2024, and September 29, 2025. The complaint claims that the company made false statements or concealed material information regarding its sole drug candidate, SLK, specifically its similarities to BIMZELX in targeting inflammatory cytokines IL-17A and IL-17F. It is alleged that the company misrepresented the purported clinical advantages of SLK's Nanobody structure, including claims that it would offer superior clinical benefits and increased tissue penetration compared to traditional monoclonal antibodies. Based on these allegations, the lawsuit asserts that Moonlake Immunotherapeutics lacked a reasonable basis for its positive statements about SLK's superiority. Investors who experienced losses during the specified period are represented in this case.Disclaimer: This news brief was created by Public Technologies  using generative artificial in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL3PzFVR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLTX","BK4139"],"gpt_icon":0},{"id":"2590055360","title":"Moonlake Immunotherapeutics Chief Scientific Officer Kristian Reich Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2590055360","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590055360?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:29","pubTimestamp":1765402185,"startTime":"0","endTime":"0","summary":"Kristian Reich, Chief Scientific Officer of Moonlake Immunotherapeutics, reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moonlake Immunotherapeutics published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 10, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL7PDGX8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Moonlake Immunotherapeutics Chief Scientific Officer Kristian Reich Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLTX","BK4139"],"gpt_icon":0},{"id":"2589358901","title":"Moonlake Immunotherapeutics Faces Class Action Lawsuit Over Securities Fraud Allegations","url":"https://stock-news.laohu8.com/highlight/detail?id=2589358901","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589358901?lang=en_us&edition=fundamental","pubTime":"2025-12-08 20:47","pubTimestamp":1765198033,"startTime":"0","endTime":"0","summary":"A class action lawsuit has been filed against Moonlake Immunotherapeutics on behalf of investors who suffered losses between March 10, 2024, and September 29, 2025, due to alleged securities fraud. The complaint asserts that the company and other defendants made false statements or concealed key information regarding its sole drug candidate, SLK. Specifically, it is alleged that SLK and BIMZELX share the same molecular targets, and that SLK's distinct Nanobody structure would not provide superior clinical benefits or increased efficacy as claimed. The suit further alleges that the company lacked a reasonable basis for its positive statements about SLK's purported advantages over traditional monoclonal antibodies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, inve","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDLbF0KR5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLTX","BK4139"],"gpt_icon":0},{"id":"2588104635","title":"Moonlake Immunotherapeutics Faces Class Action Lawsuit Over Alleged Securities Fraud","url":"https://stock-news.laohu8.com/highlight/detail?id=2588104635","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588104635?lang=en_us&edition=fundamental","pubTime":"2025-12-03 20:44","pubTimestamp":1764765851,"startTime":"0","endTime":"0","summary":"A class action lawsuit has been filed against Moonlake Immunotherapeutics on behalf of investors who suffered losses between March 10, 2024, and September 29, 2025. The complaint alleges that the company made false statements and concealed crucial information about its sole drug candidate, SLK. Specifically, it is claimed that Moonlake misrepresented SLK's molecular similarities to another drug, BIMZELX, and overstated the potential clinical benefits of SLK's Nanobody structure. The lawsuit asserts that the company lacked a reasonable basis for its positive claims regarding SLK's superiority over monoclonal antibodies. Investors affected by these alleged misrepresentations are seeking remedies through the class action process.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as f","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDLcdHS4X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLTX"],"gpt_icon":0},{"id":"2588205822","title":"MoonLake Immunotherapeutics Faces Class Action Lawsuit Alleging Securities Fraud","url":"https://stock-news.laohu8.com/highlight/detail?id=2588205822","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588205822?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:42","pubTimestamp":1764679331,"startTime":"0","endTime":"0","summary":"A class action lawsuit has been filed against Moonlake Immunotherapeutics on behalf of investors who suffered losses between March 10, 2024, and September 29, 2025. The complaint alleges that the company made false statements or concealed information regarding its sole drug candidate, SLK. Specifically, it is claimed that SLK and BIMZELX share the same molecular targets, and that SLK's unique Nanobody structure does not provide a superior clinical benefit or increased tissue penetration compared to traditional monoclonal antibodies. As a result, the lawsuit contends that the company lacked a reasonable basis for its positive statements about SLK's purported advantages over monoclonal antibodies. Investors who believe they were affected by these actions are encouraged to seek legal advice.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL3fxjWs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLTX"],"gpt_icon":0},{"id":"2586478217","title":"MoonLake Immunotherapeutics Faces Class Action Lawsuit Over Alleged Securities Fraud","url":"https://stock-news.laohu8.com/highlight/detail?id=2586478217","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586478217?lang=en_us&edition=fundamental","pubTime":"2025-11-25 20:42","pubTimestamp":1764074534,"startTime":"0","endTime":"0","summary":"A class action securities lawsuit has been filed against Moonlake Immunotherapeutics on behalf of investors who suffered losses between March 10, 2024, and September 29, 2025. The complaint alleges that the company made false statements or concealed information regarding its sole drug candidate, SLK. Specifically, it is claimed that SLK and BIMZELX share the same molecular targets, that SLK's nanobody structure would not provide a superior clinical benefit over BIMZELX, and that expected increased tissue penetration would not result in greater clinical efficacy. The lawsuit asserts that the company lacked a reasonable basis for claiming SLK's superiority to monoclonal antibodies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moonlake ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDLHyPC6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLTX"],"gpt_icon":0},{"id":"2585117555","title":"MoonLake Immunotherap Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2585117555","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585117555?lang=en_us&edition=fundamental","pubTime":"2025-11-21 19:33","pubTimestamp":1763724780,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MLTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 21, 2025 06:33 ET (11:33 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLTX"],"gpt_icon":0},{"id":"2585311278","title":"MoonLake price target lowered to $26 from $30 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2585311278","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585311278?lang=en_us&edition=fundamental","pubTime":"2025-11-21 19:10","pubTimestamp":1763723415,"startTime":"0","endTime":"0","summary":"H.C. Wainwright lowered the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $26 from $30 and keeps a Buy rating on the shares. The fir...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/moonlake-price-target-lowered-to-26-from-30-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/moonlake-price-target-lowered-to-26-from-30-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MLTX","BK4139"],"gpt_icon":0},{"id":"2584949741","title":"MoonLake Immunotherapeutics Faces Investor Class Action Over Alleged Securities Fraud","url":"https://stock-news.laohu8.com/highlight/detail?id=2584949741","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584949741?lang=en_us&edition=fundamental","pubTime":"2025-11-19 21:00","pubTimestamp":1763557228,"startTime":"0","endTime":"0","summary":"A class action lawsuit has been filed against Moonlake Immunotherapeutics on behalf of investors who suffered losses between March 10, 2024, and September 29, 2025. The complaint alleges that the company issued false statements or concealed key information regarding its sole drug candidate, SLK. Specifically, it is claimed that Moonlake did not disclose that SLK and BIMZELX share the same molecular targets, that SLK's unique Nanobody structure would not provide a superior clinical benefit over the traditional monoclonal antibody structure of BIMZELX, and that the expected increased tissue penetration of SLK would not result in improved clinical efficacy. The lawsuit asserts that these factors undermined the company's positive statements about SLK's purported advantages. The legal action seeks to recover losses for affected shareholders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and tim","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nNDL73MnrD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLTX"],"gpt_icon":0},{"id":"2582379825","title":"Moonlake Immunotherapeutics Faces Class Action Lawsuit Over Alleged Securities Fraud","url":"https://stock-news.laohu8.com/highlight/detail?id=2582379825","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582379825?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:50","pubTimestamp":1762951816,"startTime":"0","endTime":"0","summary":"A class action lawsuit has been filed against Moonlake Immunotherapeutics on behalf of investors who suffered losses between March 10, 2024 and September 29, 2025. The complaint alleges that the company made false or misleading statements regarding its sole drug candidate, SLK. Specifically, it is claimed that Moonlake concealed that SLK and another drug, BIMZELX, share the same molecular targets, and that SLK's unique Nanobody structure would not provide superior clinical benefits or increased tissue penetration compared to traditional monoclonal antibodies. Based on these factors, the lawsuit argues that the company lacked a reasonable basis for its positive statements about SLK's purported advantages. The litigation seeks to recover losses for affected shareholders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL7p6z7H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLTX"],"gpt_icon":0},{"id":"2581000256","title":"MoonLake Immunotherapeutics Faces Class Action Lawsuit Alleging Securities Fraud","url":"https://stock-news.laohu8.com/highlight/detail?id=2581000256","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581000256?lang=en_us&edition=fundamental","pubTime":"2025-11-07 20:42","pubTimestamp":1762519336,"startTime":"0","endTime":"0","summary":"A class action lawsuit has been filed against Moonlake Immunotherapeutics on behalf of investors who suffered losses between March 10, 2024, and September 29, 2025, due to alleged securities fraud. The complaint alleges that the company made false statements or concealed information regarding its sole drug candidate, SLK. Specifically, it is claimed that SLK and BIMZELX target the same inflammatory cytokines, and that SLK's unique Nanobody structure would not provide a clinical benefit or increased efficacy over BIMZELX's traditional monoclonal structure. The lawsuit asserts that Moonlake lacked a reasonable basis for its positive statements about SLK's purported superiority. The law firm Levi & Korsinsky is representing shareholders in this case.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should no","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL3p5bLL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"MoonLake Immunotherapeutics Faces Class Action Lawsuit Alleging Securities Fraud","news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLTX"],"gpt_icon":0},{"id":"2581076110","title":"MoonLake Immunotherapeutics Reports Q3 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2581076110","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581076110?lang=en_us&edition=fundamental","pubTime":"2025-11-07 14:54","pubTimestamp":1762498451,"startTime":"0","endTime":"0","summary":"Moonlake Immunotherapeutics ( ($MLTX) ) has released its Q3 earnings. Here is a breakdown of the information Moonlake Immunotherapeutics presented ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/moonlake-immunotherapeutics-reports-q3-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/moonlake-immunotherapeutics-reports-q3-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MLTX"],"gpt_icon":0},{"id":"2581255040","title":"RBC Capital Sticks to Its Hold Rating for MoonLake Immunotherapeutics (MLTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581255040","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581255040?lang=en_us&edition=fundamental","pubTime":"2025-11-07 09:48","pubTimestamp":1762480102,"startTime":"0","endTime":"0","summary":"In a report released on November 5, Brian Abrahams from RBC Capital maintained a Hold rating on MoonLake Immunotherapeutics, with a price target of...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-its-hold-rating-for-moonlake-immunotherapeutics-mltx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-its-hold-rating-for-moonlake-immunotherapeutics-mltx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MLTX"],"gpt_icon":0},{"id":"1147778014","title":"Stock Track | MoonLake Immunotherapeutics Plummets 5.10% Amid Investor Class Action Lawsuit","url":"https://stock-news.laohu8.com/highlight/detail?id=1147778014","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147778014?lang=en_us&edition=fundamental","pubTime":"2025-11-07 00:04","pubTimestamp":1762445083,"startTime":"0","endTime":"0","summary":"MoonLake Immunotherapeutics (MLTX) saw its stock price plummet by 5.10% in Thursday's intraday trading, as investors reacted to news of a class action lawsuit filed against the company. The lawsuit...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MLTX"],"gpt_icon":0},{"id":"2581035364","title":"Wedbush Sticks to Their Buy Rating for MoonLake Immunotherapeutics (MLTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581035364","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581035364?lang=en_us&edition=fundamental","pubTime":"2025-11-06 11:16","pubTimestamp":1762398963,"startTime":"0","endTime":"0","summary":"Wedbush analyst Yun Zhong maintained a Buy rating on MoonLake Immunotherapeutics yesterday and set a price target of $18.00. Zhong covers the Healt...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wedbush-sticks-to-their-buy-rating-for-moonlake-immunotherapeutics-mltx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wedbush-sticks-to-their-buy-rating-for-moonlake-immunotherapeutics-mltx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MLTX"],"gpt_icon":0},{"id":"2581470666","title":"MoonLake Immunotherapeutics: Strong Financials and Promising Clinical Developments Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2581470666","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581470666?lang=en_us&edition=fundamental","pubTime":"2025-11-06 04:05","pubTimestamp":1762373151,"startTime":"0","endTime":"0","summary":"Analyst Rami Katkhuda from LifeSci Capital maintained a Buy rating on MoonLake Immunotherapeutics and keeping the price target at $16.00. Rami Katk...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/moonlake-immunotherapeutics-strong-financials-and-promising-clinical-developments-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/moonlake-immunotherapeutics-strong-financials-and-promising-clinical-developments-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MLTX"],"gpt_icon":0},{"id":"2581701397","title":"MoonLake Immunotherapeutics: Promising Clinical Trials and Strategic Regulatory Advances Boost Confidence in Sonelokimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2581701397","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581701397?lang=en_us&edition=fundamental","pubTime":"2025-11-06 01:35","pubTimestamp":1762364152,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Phil Nadeau has maintained their bullish stance on MLTX stock, giving a Buy rating on November 3. Phil Nadeau’s rating is based on...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/moonlake-immunotherapeutics-promising-clinical-trials-and-strategic-regulatory-advances-boost-confidence-in-sonelokimab-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/moonlake-immunotherapeutics-promising-clinical-trials-and-strategic-regulatory-advances-boost-confidence-in-sonelokimab-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MLTX","BK4139"],"gpt_icon":0},{"id":"2581722432","title":"BRIEF-MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2581722432","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581722432?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:40","pubTimestamp":1762346441,"startTime":"0","endTime":"0","summary":"BRIEF-MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten OfferingNov 5 (Reuters) - MoonLake Immunotherapeutics MLTX.O:MOONLAKE IMMUNOTHERAPEUTICS ANNOUNCES PRICING OF $75 MILLIO","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nTUA5VYYZ3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLTX","BK4139"],"gpt_icon":0},{"id":"2581721082","title":"MoonLake Q3 EPS $(1.10) Misses $(0.88) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2581721082","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581721082?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:13","pubTimestamp":1762344809,"startTime":"0","endTime":"0","summary":"MoonLake (NASDAQ:MLTX) reported quarterly losses of $(1.10) per share which missed the analyst consensus estimate of $(0.88) by 25.14 percent. This is a 96.43 percent decrease over losses of $(0.56) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48649460/moonlake-q3-eps-1-10-misses-0-88-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QLD",".IXIC","QID","BK4139","MNQmain","MLTX","USAW.SI","PSQ","TQQQ","TSYW.SI","SQQQ","NQmain","USJW.SI","NVIW.SI"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.moonlaketx.com","stockEarnings":[{"period":"1week","weight":-0.058},{"period":"1month","weight":0.0647},{"period":"3month","weight":-0.7432},{"period":"6month","weight":-0.7152},{"period":"1year","weight":-0.7414},{"period":"ytd","weight":-0.7509}],"compareEarnings":[{"period":"1week","weight":0.006},{"period":"1month","weight":0.0391},{"period":"3month","weight":0.0326},{"period":"6month","weight":0.128},{"period":"1year","weight":0.1585},{"period":"ytd","weight":0.1685}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or axial spondyloarthritis. MoonLake Immunotherapeutics was incorporated in 2021 and is headquartered in Zug, Switzerland.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.024369},{"month":2,"riseRate":0.4,"avgChangeRate":0.077053},{"month":3,"riseRate":0.6,"avgChangeRate":0.026866},{"month":4,"riseRate":0.2,"avgChangeRate":-0.112596},{"month":5,"riseRate":0.4,"avgChangeRate":0.086858},{"month":6,"riseRate":0.8,"avgChangeRate":0.175967},{"month":7,"riseRate":0.6,"avgChangeRate":0.073307},{"month":8,"riseRate":0.6,"avgChangeRate":0.090179},{"month":9,"riseRate":0.4,"avgChangeRate":-0.166769},{"month":10,"riseRate":0.6,"avgChangeRate":0.061028},{"month":11,"riseRate":0.666667,"avgChangeRate":0.098535},{"month":12,"riseRate":0.5,"avgChangeRate":0.083222}],"exchange":"NASDAQ","name":"MoonLake Immunotherapeutics","nameEN":"MoonLake Immunotherapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MoonLake Immunotherapeutics(MLTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest MoonLake Immunotherapeutics(MLTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"MoonLake Immunotherapeutics,MLTX,MoonLake Immunotherapeutics股票,MoonLake Immunotherapeutics股票老虎,MoonLake Immunotherapeutics股票老虎国际,MoonLake Immunotherapeutics行情,MoonLake Immunotherapeutics股票行情,MoonLake Immunotherapeutics股价,MoonLake Immunotherapeutics股市,MoonLake Immunotherapeutics股票价格,MoonLake Immunotherapeutics股票交易,MoonLake Immunotherapeutics股票购买,MoonLake Immunotherapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MoonLake Immunotherapeutics(MLTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest MoonLake Immunotherapeutics(MLTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction